Posts Tagged ‘paion’
PAION Announces Patient Recruitment For Phase IIa Study With Its Short Acting Anesthetic/Sedative CNS 7056 Successfully Completed
The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces the successful completion of the Recruitment for the Phase IIa clinical trial assessing the new short-acting intravenous anesthetic/sedative CNS 7056 in patients undergoing endoscopy of the upper gastrointestinal tract. “Again our development team has beaten our expectations. We will be able to provide headline data by November,” commented Dr.
PAION AG: Phase Ib And IIa Studies Of The Anesthetic/Sedative CNS 7056 On Track
The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) today announces that the respective Data Monitoring Committees (DMCs), after predefined interim analyses, recommended that the Company should proceed as planned with their Phase IIa study as well as Phase Ib of CNS 7065, a new short-acting intravenous anesthetic/sedative.
PAION Initiates Phase Ib Study Of The Anesthetic/Sedative CNS 7056 In Volunteers Undergoing Colonoscopy
The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) announces the start of a Phase Ib multiple dose study with the new short-acting intravenous anesthetic/sedative CNS 7056 in volunteers undergoing colonoscopy. The randomized, open, dose-escalation multiple dose Phase Ib study will evaluate the sedation and recovery profile of CNS 7056 in volunteers undergoing colonoscopy.
PAION Initiates Phase II Trial With Its Anesthetic/Sedative CNS 7056
The biopharmaceutical company PAION AG (ISIN DE000A0B65S3; Frankfurt Stock Exchange, Prime Standard: PA8) announces the commencement of the initial Phase II study with CNS 7056, a new short-acting intravenous anesthetic/sedative. The study will enroll 100 patients undergoing diagnostic endoscopy of the upper gastrointestinal tract.
Rx Drug Compare
Translator
By N2H